Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660817 | 0.88 | KEAP1 (0.49) | TSHRBCL2A1KEAP1NFE2L2L3MBTL1 | |
| SCHEMBL1826174 | 0.87 | MLYCD (0.44) | MLYCDALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL27451463 | 0.87 | MLYCD (0.44) | MLYCDKMT2AALDH1A1RAB9AHSD17B10 | |
| SCHEMBL3503827 | 0.85 | MLYCD (0.43) | MLYCDMEN1KMT2AALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL6216388 | 0.85 | MLYCD (0.43) | MLYCDALDH1A1RAB9APDK2 | |
| SCHEMBL6295798 | 0.85 | MLYCD (0.48) | MLYCDTSHRCYP2C19CYP3A4CYP2C9 | |
| SCHEMBL3225600 | 0.85 | L3MBTL1 (0.39) | MLYCDTSHRPOLBBCL2A1MEN1 | |
| SCHEMBL4838543 | 0.84 | MLYCD (0.43) | MLYCDPOLBMEN1KMT2ANPC1 | |
| SCHEMBL8332394 | 0.84 | MLYCD (0.42) | MLYCDTSHRALDH1A1NPC1MAPT | |
| SCHEMBL1624928 | 0.84 | NOTUM (0.48) | MLYCDTSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067771-A1 | Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds | EPFL Ecole Polytechnique Fédérale de Lausanne (CH) | 2009-06-10 | — | — | EP | disclosed |
| CN-1441673-A | 4,5-dihydro-thiazo-2-ylamine derivatives and their use as NO-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-10 | — | — | CN | disclosed |
| US-6420566-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| US-5420275-A | Chemiluminescent assay, tumors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0491477-A1 | Pyridopyridazine compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1992-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | ALK, QDPR, CYP3A7 | MLYCD 1894/4885TSHR 1362/4885HTT 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.